# Prevalence of SARS-CoV-2 infection in the Luxembourgish population – the CON-VINCE study

Chantal J. Snoeck<sup>1\*</sup>, Michel Vaillant<sup>8\*</sup>, Tamir Abdelrahman<sup>9\*</sup>, Venkata P. Satagopam<sup>7,12</sup>, Jonathan D. Turner<sup>1</sup>, Katy Beaumont<sup>5</sup>, Clarissa P. C. Gomes<sup>3</sup>, Joëlle V. Fritz<sup>4</sup>, Valerie E. Schröder<sup>2,3</sup>, Anne Kaysen<sup>3</sup>, Lukas Pavelka<sup>2,3</sup>, Lara Stute<sup>2,3</sup>, Guilherme Ramos Meyers<sup>3</sup>, Laure Pauly<sup>3</sup>, Maxime Hansen<sup>2,4</sup>, Claire Pauly<sup>2,3</sup>, Gloria A. Aguayo<sup>6</sup>, Magali Perquin<sup>6</sup>, Anne-Marie Hanff<sup>4</sup>, Soumyabrata Ghosh<sup>7</sup>, Manon Gantenbein<sup>10</sup>, Laetitia Huiart<sup>6</sup>, Markus Ollert<sup>1,12,x</sup>, Rejko Krüger<sup>2,4,7,x</sup> on behalf of the CON-VINCE study group<sup>#</sup>

\*co-first authors

<sup>x</sup>co-senior authors

<sup>#</sup> (all study group members are listed in the acknowledgment part)

Corresponding author: rejko.krueger@lih.lu

#### Affiliations

- 1. Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, L-4354 Luxembourg
- 2. Department of Neurology, Centre Hospitalier de Luxembourg, Luxembourg, L-1210
- 3. Clinical and Experimental Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg
- 4. Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg
- 5. Integrated Biobank of Luxembourg (IBBL), Dudelange, L-3555 Luxembourg
- 6. Population Health Department, Luxembourg Institute of Health. Strassen L-1445 Luxembourg
- 7. Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg
- 8. Competence Center for Methodology and Statistics, Luxembourg Institute of Health. Strassen L-1445 Luxembourg
- 9. Department of Microbiology, Laboratoire national de santé, Dudelange, L-3555, Luxembourg

- 10. Clinical and Epidemiological Investigation Center (CIEC), Luxembourg Institute of Health. Strassen L-1445 Luxembourg
- 11. Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense C, Denmark
- 12. ELIXIR-Luxembourg Node, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg

# Abstract

#### BACKGROUND:

The World Health Organization declared the outbreak of coronavirus disease to be a public health emergency of international concern on January 30, 2020. The first SARS-CoV-2 infection was subsequently detected in Luxembourg on February 29, 2020. Representative population-based data, including asymptomatic individuals for assessing the viral spread and immune response was, however, lacking worldwide.

#### METHODS:

Using a panel-based method, we recruited a representative sample of the Luxembourgish population based on age, gender and residency for testing for SARS-CoV-2 infection and antibody status in order to define prevalence irrespective of clinical symptoms. Participants were contacted via email to fill an online questionnaire before biosampling at local laboratories. Participants provided information related to clinical symptoms, epidemiology, socioeconomic and psychological assessments and underwent biosampling, rRT-PCR testing and serology for SARS-CoV-2.

#### **RESULTS**:

A total of 1862 individuals were included for our representative sample of the general Luxembourgish population. We detected an ongoing SARS-CoV-2 infection based on rRT-PCR in 5 participants. h Four of the SARS-CoV-2 infected participants were oligosymptomatic and one was asymptomatic. Overall, 35 participants (1.97%) had developed a positive IgG response, of whom 11 self-reported to have previously received a positive rRT-PCR diagnosis of SARS-CoV-2 infection. Our data indicate a prevalence of 0.3% for active SARS-CoV-2 infection in the Luxembourgish population between 18 and 79 years of age.

#### CONCLUSIONS:

Luxembourgish residents show a low rate of acute infections after 7 weeks of confinement and present with an antibody profile indicative of a more recent immune response to SARS-CoV-2. All infected individuals were oligo- or asymptomatic. Bi-weekly follow-up visits over the next 2 months will inform about the viral spread by oligo- and asymptomatic carriers and the individual changes in the immune profile.

## Introduction

On March 11, 2020, the World Health Organization (WHO) declared the ongoing outbreak of coronavirus disease (COVID-19) a pandemic (World Health Organization (WHO), 2020b). The pathogen responsible for COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in Wuhan, Hubei Province, China (Huang et al., 2020). By May 6, 2020, the illness had rapidly spread to over 210 countries, affecting over 3 million people and claiming more than 200,000 lives worldwide (World Health Organization (WHO), 2020a).

The first SARS-CoV-2 infection in Luxembourg was detected on February 29, in a person who had just returned from Italy. Luxembourg is a country with 626,000 inhabitants in the heart of Europe and has borders with Belgium, France, and Germany (Statec; 2020). It is highly connected to its neighbors, with more than 200,000 cross-border employees commuting to Luxembourg. On March 12, the government communicated measures taken to tackle the spread of the Coronavirus. These measures entered into force on March 16. As in many other countries, all educational institutions were closed, employees were encouraged to work from home whenever possible, all non-essential activities were cancelled or closed, including all commercial and business activities involving direct contact with customers (except essential products and services). Travel was restricted for the general public (with limited exceptions such as helping and caring for elderly or disabled people, or travelling to work, and border controls were implemented). By May 6, 50533 individuals had been tested, with 3851 individuals tested positive for SARS-CoV-2 and the disease accounted for 98 deaths in Luxembourg so far (Government of the Grand Duchy of Luxembourg, 2020: https://msan.gouvernement.lu/en/dossiers/2020/corona-virus.html).

In addition to the direct effects of the pandemic, the confinement and quarantine measures linked to the coronavirus pandemic also have a substantial socio-economic and psychological impact. Besides initiating a global recession, psychological counselling services opened worldwide and will soon demonstrate the psychological cost of the pandemic. Further analyses over time will provide insights into the expansion of the socio-economic and psychological impact of the coronavirus pandemic.

First studies currently aim at better understanding the dynamics of the pandemic and to improve measures to confine the spread of SARS-CoV-2 in the absence of effective medication or of vaccines (Gudbjartsson et al., 2020). Here the role of asymptomatic SARS-CoV-2-positive individuals for the propagation becomes more and more important (Streeck et al., 2020; Lai et al., 2020; Bai et al., 2020). Systematic screening of a representative population irrespective of clinical symptoms may detect asymptomatic persons who are expected to play an important role in the disease transmission and inform about the overall infection rate in a population. We used reverse-transcription polymerase chain reaction (rRT-PCR) to identify asymptomatic or oligosymptomatic carriers of SARS-CoV-2 and serology-based testing to identify participants that had developed an immune response. In addition, questionnaires on clinical symptoms, epidemiological, and

socioeconomic factors were used to better understand the nature, dynamics of spread, and transmission along with the prevalence of the virus in the population.

### Materials and Methods

#### Study design

This study is a nation-wide, observational study aiming to define the prevalence of SARS-CoV-2 infections in the Luxembourgish population. Here we present the baseline assessment of the CON-VINCE cohort. To capture the dynamics and impact of the virus spreading over time, the cohort will be follow-up over 12 months. An intensive data and sample collection will be performed every 2 weeks for the first 2 months (5 times in total) with a final follow-up 1 year after the participants' inclusion in the study. At each collection time-point, blood, nasal and oropharyngeal swabs are collected, and participants also fill in questionnaires on epidemiological and clinical data as well as socioeconomic and psychological well-being. The provision of a stool sample at each biosampling time point is optional for all participants. To allow for data harmonization and international collaboration the overall data set includes questions recommended by the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), hosted by the Centre for Tropical Medicine and Global Health at the University of Oxford (WHO), and the Weizmann Institute (Rossman et al., 2020) adapted to the Luxembourgish environment (Börsch-Supan et al., 2013; Börsch-Supran, 2019).

The study design (**Figure 1**) accounts for the need to recruit a representative sample of the Luxembourgish population (>18 years old) within a short time frame in the context of the already existing confinement measures. All participants were tested for SARS-CoV-2 by rRT-PCR. Additionally, serological testing for virus-specific antibodies (IgA and IgG against SARS-CoV-2) was performed. Participants who were either asymptomatic or oligosymptomatic, from the clinical point of view, are being followed up longitudinally regardless of the SARS-CoV-2 positive or negative status. Symptomatic individuals positive for SARS-CoV-2 with COVID-19 disease contribute to the baseline assessment but are not followed-up.

The baseline questionnaire captured demographic data, medical history and behavioral and psychological data. Demographic data included age, gender, origin, residential areas as well as marital status, number of children, the household composition, and the age of the household members. As socio-economic-status is intimately linked to the incidence and severity of respiratory tract infections, we obtained information on educational level, professional background, current employment status, income, and the house-ownership.

Subjects provided information on their medical history, including cardiac, hepatic, metabolic, pulmonary, neurological, hematological and oncological comorbidities, and gynecological history. Prior history of allergies and smoking were recorded. A self-reported description of chronic medication taken regularly was mandatory. COVID-19-related data included whether the participants have already been tested for the SARS-CoV-2, indicating the date and the result of the test. Additionally, we invited subjects to document if they had travelled to an area with confirmed SARS-CoV-2 infections during the 14 days prior to their participation in the study. Environmental conditions of the household were obtained (e.g., the possibility of quarantine of one household member, etc.).

To assess psychological and behavioural factors or changes during the pandemic, we asked participants to quantify physical activity, the frequency of leaving the house, alcohol consumption, screen time, as well as social contact through technological devices. Their compliance with the recommendations and restrictions issued by the Luxembourgish government during the pandemic was measured by a series of questions compiled from the WHO and Luxembourg Health Directorate guidelines (WHO 2014, Luxembourg Health Directorate, 2020). Depressive symptoms are and further will be assessed in the multiple follow-up questionnaires using the Center for Epidemiologic Studies Depression Scale (CES-D Scale) (Radloff, 1977). Presence and severity of anxiety is measured in the multiple follow-up questionnaires using the seven items Generalized Anxiety Disorder Assessment (GAD-7) (Spitzer et al., 2006). Participants' perception of their psychosocial stress level was assessed using the 4-item Perceived Stress Scale (PSS-4) on a 5-point Likert scale (Cohen et al., 1983). Social isolation and loneliness were assessed with the 3-item UCLA Loneliness Scale (short version) (Hughes et al., 2004). The Brief Resilience Scale (BRS) (Smith et al., 2008) measures resilience or the ability to recover from a stressful period or event using 6 items, scored on a 5-point Likert scale. Five personality traits (Extraversion, Agreeableness, Conscientiousness, Emotional Stability and Openness) are assessed using the Big Five Inventory-10 (BFI-10) (Rammstedt and John, 2007).

The bi-weekly follow-up questionnaires will cover participants' present health and psychological status. Current health status will focus on signs and symptoms associated with SARS-CoV-2 during the intervening period and medication (e.g., paracetamol, cough medicine, NSAIDs) for symptom relief. Psychological data that will be collected during the follow-up questionnaires include CES-D, GAD-7, PSS-4 and UCLA loneliness scale. BRS and BFI-10 are administered again during the yearly follow-up. As social adversity has been linked to respiratory tract infections (Elwenspoek et al., 2017) the final questionnaire includes the 28-item Childhood Trauma Questionnaire (Bernstein et al., 2003), to retrospectively assess distress during childhood together with a questionnaire covering the principal psychosocial stressors in adulthood such as divorce, job loss or the death of a family member (Turner at al., 2020). The questionnaires, as well as the questionnaire schedule, are included in **Supplementary Material 1**.

The study was approved by the national research ethics committee (Comité National d'Ethique de Recherche, CNER), under reference 202004/01, and by the Luxembourgish Ministry of Health under reference 831x6ce0d. The study has been submitted for registration on ClinicalTrials.gov (NCT04379297).

### Population screening

The CON-VINCE study was launched on April 15, and participants randomly selected from a representative panel, which consented to the study and fulfilled the inclusion criteria, were enrolled from April 15 until May 5, 2020. Participants filled the online questionnaire and accomplished biosampling in approved diagnostic laboratories spread all over the country. Participants vulnerable to SARS-CoV-2 infection were sampled at home. A total of 1862 participants successfully completed the questionnaire and were biosampled.

### Sample size calculation

Given the rapidly evolving incidence of infected cases on April 10, when the study protocol of CON-VINCE was established and based on an unknown number of asymptomatic people, a prevalence of 50% of cases was assumed, that would lead to the largest sample size. It would allow estimating any other prevalence figure.

Assuming a 95% confidence interval and a precision of 2.5% around the estimate of prevalence, the required sample size was a minimum of 1537 participants. The chosen sampling strategy for the sample to be representative of the general population was to stratify by gender, age categories (10 years from 18 years and above), and electoral districts. To compensate for non-response and potential drop-outs during the study, over 2000 individuals were invited to join the study.

#### Sampling

According to the National Institute of Statistics and Economic Studies of the Grand Duchy of Luxembourg (Statec), the national population aged 18 years and over was 514,921 at the beginning of the study. This constituted the sampling frame.

An equal allocation probability was used (chance for all individuals of the same age category and gender to be selected) proportional to size (of the population) without replacement (the same individual could not be selected twice). The selection probability for unit i (for example 60-69y) in stratum h (for example men) equaled nhZhi, where nh was the sample size for stratum h, and Zhi was the relative size of unit i in stratum h. The relative size equaled Mhi/Mh, which was the ratio of the size measure for unit i in stratum h (Mhi = number of men aged 65-69y) to the total of all size measures for stratum h (Mh = number of men) (SAS Institute Inc, 2009).

Due to constraints related to the emerging pandemic, the sample of participants was enrolled through the use of a non-probabilistic web panel (unknown probability to opt-in) of 18,000 members by a survey company to access participants within the sampling plan. A deterministic random bit generator (DRBG) within strata was used to apply the equal allocation probability proportional to size.

### Acquisition and Preparation of Samples

The first round of biosampling was performed from April 16 onwards at routine medical diagnostic laboratories (BioneXt, Ketterthill and Laboratories Réunis) throughout Luxembourg using standardised study collection kits containing all the required materials provided by the Integrated Biobank of Luxembourg (IBBL). Collection kits included the mandatory blood samples and nose and throat swabs, as well as an optional stool collection kit (**Supplementary Table 1**). Following collection, blood, nose and throat swabs were maintained at 2-8°C and transported within 24h to the IBBL for processing. Participants collected stool samples at home and sent them in provided transport boxes to the IBBL using the regular postal service. Blood and stool samples were processed in the IBBL. Swab samples were transferred to the Laboratorie National de la Santé (LNS) for rRT-PCR SARS-CoV-2 testing (**Supplementary Table 1**). Serum was transferred at - 20°C to the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) for serology testing. Leftover swab samples and residual RNA from swab samples were returned to IBBL for aliquoting and storage, within 24h following the initial transfer to LNS. The sampling procedure will be maintained for the follow-up visits.

#### Data Integration, Storage and Access

As part of our Case Report Forms (CRFs) (**Supplementary Material 1**) was based on ISARIC COVID19 Core CRF (<u>https://isaric.tghn.org/COVID-19-CRF/</u>), our data is aligned with international standards and can be easily harmonized and pooled with other studies facilitating cross-study analysis. Encrypted pseudonymised raw data has been deposited in the Luxembourg Centre for Systems Biomedicine (LCSB) secure repository. Upon arrival, all pseudonymised questionnaire and clinical data is curated and mapped to associated rRT-PCR and serology data through each participant's pseudonymised ID with corresponding sample kit ID (subject-sample-mapping) and maintained in REDCap (www.project-redcap.org), personal information was maintained separately in a proprietary secured server (SMASCH). REDCap provides a complete audit trail for study data (https://www.project-redcap.org). This integrated, curated and processed data is available through an access-controlled study-specific data integration and analysis platform (ADA). The ELIXIR-Luxembourg node (ELIXIR-LU http://elixir-luxembourg.org) will provide long-term hosting, ensuring the sustainability of CON-VINCE data. Data flows are highlighted in **Figure 2**).

#### **RT-PCR**

Automated RNA extraction was performed using a STARMag 96 x 4 Universal Cartridge Kit (Seegene) for all swabs. SARS-CoV-2 detection was carried out using the Allplex 2019 n-CoV Assay (Seegene) according to the manufacturer's instructions. The Allplex 2019 n-CoV assay amplifies specific regions in the RdRP, N genes (specific SARS-CoV-2 detection) and E gene

(pan-*Sarbecovirus* detection). Inconclusive results, i.e. samples where only the RdRP or the N gene was amplified, a second manual RNA extraction using the QIAamp viral RNA minikit (Qiagen, Venlo, the Netherlands) followed by duplicate RNA testing with in house assays including the E gene rRT-PCR (Corman et al., 2020), N gene (N1 target) rRT-PCR and human RNAse P rRT-PCR as sample quality control (CDC), using TaqPath 1-Step RT-qPCR Master Mix (Life Technologies, Merelbeke, Belgium). Viral RNA from BetaCoV/Germany/BavPat1/2020 strain (Ref 026N-03889), kindly provided by the Charité-Universitätsmedizin Berlin (Corman et al., 2020) through the European Virus Archive Global platform, was used as positive control. Inconclusive samples were also screened with the FTD SARS-CoV-2 assay (Fast Track Diagnostics, Eschsur-Alzette, Luxembourg), which detects N and ORF1ab genes of SARS-CoV-2. As outlined in **Figure 3**, all samples that were only positive for N gene in the original rRT-PCR, were considered positive when a Ct value < 40 was obtained for at least one replicate for 2 viral genes in 2 different second-round rRT-PCRs on the same sample.

### Serology

Anti-SARS-CoV-2 IgA and IgG were determined by CE-labelled enzyme-linked immunosorbent assay (ELISA) kits (most recent versions of Euroimmun Anti-SARS-CoV-2 ELISA IgA and Euroimmun Anti-SARS-CoV-2 ELISA IgG) according to the manufacturer's instructions and as described by others (Streeck et al., 2020). The optical density (OD) was measured at 450 nm from which background OD measured at 650 nm was deducted. OD ratios were calculated by dividing the resulting OD by the OD of the calibrator, which is included in the kit. In house quality controls, prepared to give an expected OD ratio of approximately three times the threshold for positivity, were included in all assays. As per the kit recommendations, samples with OD ratios <0.8 were considered negative, OD ratios  $\geq$ 1.1 were considered positive and samples with intermediate OD ratios ( $\geq$ 0.8, <1.1) were judged borderline positive.

A cohort of anonymised archived sera collected from adults during the two winter seasons (cohort A, 2018, n=92; 2019, n=93) prior to the start of the COVID-19 pandemic were tested by both IgA and IgG ELISAs to assess their specificity. All sera had been collected for other purposes than respiratory disease diagnosis. A second cohort of anonymized sera (cohort B, 2020, n=37) was collected at the Centre Hospitalier de Luxembourg (CHL) from patients with documented COVID-19 disease and positive rRT-PCR results. The delay between onset of symptoms and blood drawing ranged from 1 to 26 days. Those sera contributed to evaluating the ELISA sensitivity. All sera with intermediate results were considered positive when calculating specificity and sensitivity.

### Statistical analyses and data presentation

Prevalence of the SARS-CoV-2 RNA infection was measured by rRT-PCR. IgA and IgG serology was also translated into seroprevalence. The infection rate was evaluated through previously reported and current rRT-PCR and IgG positivity. Prevalence estimates were calculated by

accounting for the design of the study, namely weights from the sampling strategy as defined by the stratification variables (gender, 10 years age categories and electoral district).

A representativeness evaluation was carried out to verify that the proportions estimated from the sample can be extrapolated to the general population. 95% confidence intervals (95%CI) were given. Sampling proportions were calculated for each strata of the sample of participants enrolled in the study as well as in the general population. The ratio of these proportions provided the weights for post stratification.

In the sense of sensitivity analyses, sampling weights were also calculated for "cantons" which is a more granular strata than electoral district.

The formula for infection rate was as follows: past or current positive PCR or IgG positive or intermediate divided by the total sample population (N=1835).

Prevalences were calculated with SAS v9.4 (SAS institute, Cary, NC, USA) except the IR and IFR where R was used with the svycipro function (Survey package) that calculates 95% confidence intervals for proportions with logit » method. Figures were prepared in R studio (R Core Team, 2019) using the tidyverse (Wickham et al. 2019), ggbeeswarm (Clarke and Sherril-Mix, 2017) and ggpubr (Kassambara, 2020) packages.

## Results

#### Cohort description

The recruitment of Luxembourg residents for the CON-VINCE study started on April 15 and was concluded on May 5 after the inclusion of 1862 individuals, thereby exceeding the minimum of 1537 participants calculated for assessing prevalence. All individuals that accomplished the baseline questionnaire online underwent biosampling. Viral rRT-PCR was performed in 1842 participants and SARS-CoV-2 specific serology for IgA and IgG was performed in 1820 individuals.

The basic epidemiological features of the study participants, such as gender, age, education, number of persons sharing the same household, and residency within the Luxembourg territory are described in **Table 1**.

### Sensitivity and specificity of SARS-CoV-2 IgA and IgG ELISAs

Two serum cohorts were used to assess the specificity and sensitivity of both IgA and IgG ELISAs. In specificity cohort A, 20/185 (10.8%) and 4/185 (2.2%) sera reacted in IgA and IgG ELISAs (positive and intermediate; **Figure 4**), leading to a specificity of 89.2% and 97.8% respectively. Only one serum was IgA and IgG positive, providing an increased specificity of 99.5% when combining both results.

Cohort B consisting of hospitalized COVID-19 patients was used to estimate assay sensitivity in relation to the time delay after symptom onset (**Table 2**). IgA and IgG ELISA sensitivity reached 92.9% and 85.7% at 15 days (d15) after symptom onset, while the combination of IgA and IgG results provided a sensitivity of 85.7% (**Table 2**).

#### Serological screening at baseline

The presence of anti-SARS-CoV-2 IgA and IgG was assessed in all sera using the CE-labeled Euroimmun assays. Overall, 201/1820 (11.0%), and 35/1820 (1.9%) participants had IgA or IgG antibody levels above the threshold considered for positivity in our study (OD ratio  $\geq 0.8$ ), respectively. Among those, 30 (1.6%) participants were positive for both IgA and IgG (**Table 3**; **Figure 5**). A positive correlation between IgA and IgG OD ratios was observed (all data, Spearman correlation coefficient *r*=0.362, *p*<0.001; *IgA positive and IgG positive only*, *r*=0.855, *p*<0.001).

#### rRT-PCR screening at study baseline

A total of 1842 upper respiratory tract swabs were analyzed by Allplex 2019 n-CoV Assay. Six (0.3%) gave inconclusive results, i.e. a positive result was only detected by N gene rRT-PCR. Low levels of SARS-CoV-2 viral RNA, as shown by the high Ct values (**Table 4**), were confirmed for 5/6 participants after retesting by additional rRT-PCRs (**Figure 3**). Despite the very low viral RNA concentrations, the repeated viral RNA detection combined with the serological response observed strongly suggested that these five participants had been infected with SARS-CoV-2. Apparently, they were in the phase of clearing the viral infection and mounting an antibody response. This is further evidenced for participant 3, who already tested positive 25 days prior to study enrolment. All participants were oligo- or asymptomatic, 2 participants had contact with a COVID-19 household member while one participant had traveled in the last 14 days (**Table 6**).

#### rRT-PCR screening prior to enrolment

A total of 138/1862 (7.4%) participants had been tested for SARS-CoV-2 by rRT-PCR prior to study enrolment, and 11 of these 138 (8.0%) tested positive. All previously rRT-PCR positive

participants were IgA and IgG seropositive at the baseline time point of our study. Conversely, 16/126 (12.7%) and 5/126 (4.0%) previously rRT-PCR negative participants had tested positive for IgA or IgG, respectively. During the period between the initial (March 16-April 3) and baseline (April 15-April 29) testing (mean interval between tests: 26.9 days, range: 13-37 days), viral clearance, shown by a negative rRT-PCR at baseline, occurred in 10/11 (90.9%), while a single participant remained positive at baseline, 25 days after initial testing (see above).

Among all IgG positive participants (n=35), only one participant reported travelling within the previous 14 days and three reported having contacts outside the household (confinement measures were already in place since March 16, 2020). Seven participants were working on-site while 13 were working from home. Thirteen (37.1%) participants reported having contact with confirmed or suspected COVID-19 cases, most of the time (11/13, 84.5%), this person being household members (**Table 6**).

A wide range of clinical symptoms were reported for the last 14 days prior to enrolment by IgG positive individuals. Symptoms ranged from none or very mild ( $\leq 2$  symptoms in 19 participants) to more substantial symptoms, including shortness of breath, chest and abdominal pain. The number of symptoms reported tended to be higher in participants with a previous rRT-PCR positive diagnostic (range 0-13, average 4.5) than in participants with no or a negative rRT-PCR result (range 0-9, average 2.5; **Table 6**). The number of symptoms reported by participants with comorbidities (n=9; average 2.3) tended to be lower than in participants with no reported comorbidities (n=26; average 3.5).

#### Prevalence evaluation

For the prevalence evaluation, two out of 1842 participants with rRT-PCR results were excluded because the gender was not defined. Participants aged > 79 years were also excluded (n=12) because representativity for the overall population was not reached for this age group. The target population for prevalence evaluation was therefore defined as people between age 18 years until age 79 years. The number of individuals with rRT-PCR and serology results available was 1830 and 1807, respectively with 4 participants negative in serology with no PCR results.

The sampling frame was used to weight the number of individuals in each cell defined by the three stratification variables. Weights were calculated by dividing each cell count from the target population by the one from the sample. It was therefore used in post-stratification.

The evaluations of prevalence used the weights to extrapolate to the target population and evaluate the 95% confidence intervals.

The time prevalence of SARS-CoV-2 RNA by rRT-PCR was 0.30% (95%CI=[0.03;0.56]) during the period of April 16 until May 5. This result translates into 1449 (95%CI=[145;2754]) people in the general population aged 18 years to 79 years.

Seroprevalence of IgA was 11.07% (95%CI=[9.54;12.60]) and that of IgG 2.09% (95%CI=[1.37;2.82]). The Infection rate was 2.06% (95%CI=[1.34, 2.77]) (**Table 7**).

As a sensitivity analysis, weights were recalculated using Luxembourg's regional cantons rather than electoral districts, a more granular geographic representation. An electoral district is composed of 2 to 5 cantons. Participants were randomly selected in the district, but as we also obtained the canton information, it was relevant to have an estimate of how the prevalence could be biased by potential clustering within districts.

Using the more granular canton approach, the time prevalence of SARS-CoV-2- rRT-PCR was 0.32% (95%CI=[0.02;0.63]) which was an estimate very close to that obtained at the district level. A similar observation could be made for the other estimated prevalence (**Supplementary Table 2**).

## Discussion

The present study provides first prevalence data on the spread of SARS-CoV-2 in the population of Luxembourg using a panel-based approach. The weighted prevalence of SARS-CoV2 carriers based on rRT-PCR reveals a low prevalence of 0.30%, which may be due to the confinement measures in place for more than 7 weeks, including social distancing for the overall population and self-isolation and quarantine. Our data suggest that between April 16 and May 5 there were 1,449 adults in Luxembourg that were oligo- or asymptomatic carriers of the SARS-CoV-2.

Similarly, low results from population screenings in Iceland were recently reported with 0.8% virus-positive individuals in an open-invitation screening and 0.6% in a random-population screening identified (Gudbjartsson et al., 2020). The relevance of assessing the contribution of asymptomatic and oligosymptomatic individuals to the dynamics of the pandemic is increasingly recognized and also motivated a study at the National Institute of Health (USA) using a similar population-based approach where participants fill questionnaires during a virtual clinical visit and are biosampled for assessing seropositivity (NCT04334954).

Of the five SARS-CoV-2 positive participants only one reported that he had travelled to a COVID-19 risk area. Two positive participants reported prior contact with a COVID-19 diseased household member. The source of infection for the other 2 SARS-CoV-2 positive participants is not clear, but most probably within Luxembourg, as travels were limited given the confinement measures in place.

For the presence of infected individuals within a household, we observed the highest percentage in households with 2 members and the lowest percentage in households with 5 or more individuals (**Suppl. Fig. 1**). This is in line with the observation in a recent German study that showed a relatively moderate increase of the secondary infection risk dependent on the household cluster size (Streeck et al., 2020).

Overall participants tested positive for an active infection of SARS-CoV-2 by rRT-PCR, were oligoor asymptomatic and presented with fewer symptoms (mean of 1.6 symptoms out of 22; SD=1.14) than individuals with negative rRT-PCR results (mean of 2.3 symptoms out of 22; SD=2.43). This underscores the relevance of infected individuals that do not display typical COVID-19 signs and symptoms for the viral spread during the pandemic.

In line with previous reports, we see males overrepresented in the group of SARS-CoV-2 positive participants (4 males versus 1 female) (Gudbjartsson et al., 2020; Guan et al., 2020). As we targeted a population >18 years old, we cannot make any direct statement on the contribution of children to the viral spread.

All of the data was collected through online questionnaires. In highly connected countries such as Luxembourg, approximately 97% of the population accesses and regularly uses the internet (International Telecommunications Union, 2019). Previously, self-reported online questionnaires have been shown to be a reliable method of accessing the clinical evolution of disease (Davies 2016), and the lack of face-to-face interaction, flexibility to complete the questionnaires at the participants' convenience, together with the perceived degree of anonymity inherent in such online questionnaires is thought to enhance data accuracy, reducing central coherence and social desirability biases at the cost of participants potentially misinterpreting the questions (Ong and Weis, 2000).

Retrospective assessment was limited to events and symptoms occurring in the previous two weeks to reduce recall bias. The rapidity with which such a self-reporting system that was accessible throughout the population was rolled out was crucially important in the pandemic situation. This rapidity means that reliable data can be provided promptly to researchers during the ongoing pandemic. Furthermore, in such an unpredictable, rapidly changing pandemic situation follow-up questionnaires can be modified as quickly as ethical approval can be obtained. The advantages were, however, counterbalanced by the possibility of survey fatigue with five survey waves in quick succession.

The geographical location of Luxembourg and the nature of the study required that several compromises were made. Luxembourg is highly multilingual and successfully recruiting a representative cohort required that study participants were offered the choice of questionnaires in French, German, English and Portuguese. The problems associated with translating questionnaires are well known (Pan and Fond 2014), and to circumvent this, we restricted the study to questionnaires that had previously been experimentally validated in all languages. As we aimed to detect asymptomatic SARS-CoV-2 carriers the ISARIC case report form was adapted to participants that had limited or no symptoms and the Luxembourgish sociodemographic situation.

There are pros and cons of using web panels for surveys. We used the services of a private company for immediate access to potential participants from all over the country and based on prior knowledge on age, gender and residency. The sample of participants to the current study was enrolled through the use of a non-probabilistic web panel (unknown probability to opt-in) of 18,000 panel members. Registration to the panel was constituted via invitation during telephone or face to face interviews as well as ad banners, media campaigns and homepage of the company. The sample was randomly drawn from the panel for each stratum defined by the crossing of the 3 stratification variables through a deterministic random bit generator (DRBG)

within strata. Individuals living across the borders were excluded as we aimed at a sample of Luxembourgish residents.

The advantages of using such a panel was the simplification of the logistics to implement the study in a short time frame in order to capture the prevalence of the infection (**Figure 6**) while the decreasing slope of the epidemics has already started. Another aspect to consider is that no hospitalised patient was included in our sample as they were not reachable through the panel.

However, online surveys may be biased samples because the respondents are self-selected whereby individuals who have strong opinions, are overrepresented, and individuals that are indifferent or apathetic are less likely to opt-in or respond. Nevertheless, we tried to correct the selection bias and under representation by first stratifying the sampling on gender, age and residency at the sampling level and second, by post stratification at the analyses level.

Overall, our study captured 6 rRT-PCR positive participants with low viral RNA levels. These may be considered negative in other studies depending on the criteria applied. The combination of retesting by additional rRT-PCRs (**Figure 3**) as well as assessment of IgA and IgG serology, however, strongly suggest that 5 of these 6 study participants were true SARS-CoV-2 positive cases with residual low viral loads and seroconversion. This is also further evidenced by one of the participants who already tested positive 25 days prior to enrolment (participant 3, see **Table 4**). Duration of SARS-CoV-2 viral shedding appears to vary widely between patients. Detection of viral RNA for 2-3 weeks after symptom onset is frequent (Kujawski et al., 2020; Wölfel et al., 2020), even in seroconverted patients, and extended viral shedding for up to 83 days was reported (Li et al., 2020). One of the study participants (participant 5, **Table 4**) was not confirmed positive after two confirmation rRT-PCR assays and did not show seroconversion until now. This patient might have been recruited at the onset of viral shedding in contrast to the other cases and/or may not mount an immune response as sometimes observed in asymptomatic patients. Longitudinal follow-up sampling as implemented in the design of our study will allow us to clarify the status of this participant at a later stage.

The frequency of seasonal hCoV infections in the general population, including adults (Monto et al., 2020), coupled with possible concomitant infections by different hCoV (Heimdal et al., 2019) suggest a limited duration of protection for each hCoV and limited cross-protection between hCoV. Nevertheless, cross-reactivity in ELISA due to past exposure to other hCoV likely partially accounts for the observed lower specificity of the anti-SARS-CoV-2 IgA ELISA used in our study. Notably, cross-reactivity in anti-SARS-CoV-2 IgA and IgG ELISAs has been documented in patients with specific seroconversion against hCoV-OC43, while baseline sera were negative (Okba et al., 2020). In Germany, the follow up of a birth cohort revealed that 19/25 (76.0%) newborns had seroconverted by 21 months of age (Dijkman et al., 2012). While the frequency of each of the four seasonal hCoV oscillates between years and regions, hCoV-OC43 (betaCoV) is usually more frequent, in patients with acute respiratory disease, especially compared to hCoV-229E (alphaCoV) (Dijkman et al., 2012; Heimdal et al., 2019; Monto et al., 2020). Aside from a lower assay specificity, discrepancies between IgA and IgG after symptom onset (Guo et al., 2020), and may explain why some participants have detectable levels of IgA but no IgG.

In this study, intermediate IgA and IgG antibody levels were assimilated to a positive serological response, as done previously (Streeck et al., 2020). Although this approach decreases specificity, the current study design allows for a careful monitoring of seroconversion trends and antibody levels over time during subsequent biosampling of study participants, which will allow us a better interpretation of evolving antibody responses. Additional immunoassays including alternative antigens or antigen fragments as well as neutralization assays will complement the panel of tests that will be performed at a later stage of the CON-VINCE study. These additional immunoprofiling data will provide a more refined assessment and evaluation of the ELISA assay results obtained at baseline level of our study.

### Outlook

The longitudinal design of our study with bi-weekly follow-ups will allow us to assess the dynamics of the pandemic in our study population along with the gradual easing of the protective measures taking place in Luxembourg as well as other European countries. This may inform about the impact of oligo- and asymptomatic carriers on the viral spread during the upcoming months. Moreover, we will be able to study immune responses via continuous serological testing and may provide information on the risk of re-infections, as knowledge about SARS-CoV-2 immunity is still limited.

## Acknowledgments

We would like to give special thanks to all participants of the CON-VINCE study. Additionally, we are very grateful for the financial support by the Fonds National de la Recherche (FNR) and the André Losch Foundation, which enabled us to carry out the project. The funders had no role in the design and conduct of the study, nor in the decision to prepare and submit the manuscript for publication.

We would like to thank the Research Luxembourg COVID-19 Task Force (Frank Glod, Paul Wilmes, Lars Geffers, Jasmin Schulz, Henri-Cauchie, Ulf Nehrbass) and Rudi Balling for their overall support of the CON-VINCE study.

Furthermore, we would like to acknowledge the Communication team of the Research Luxembourg COVID-19 Task Force (Sabine Schmitz, Arnaud D'Agostini, Didier Gossens) for their excellent work and support during the implementation of CON-VINCE.

We would like to thank Philippe Lamesch for important and successful fundraising for research on COVID-19 in Luxembourg.

We thank the European Commission for the support of the European Virus Archive Global platform and the provision of SARS-CoV-2 material.

Furthermore, we acknowledge the joint effort of members of the CON-VINCE Study Group as listed below:

Tamir Abdelrahman, Geeta Acharya, Gloria Aguayo, Pinar Alper, Wim Ammerlaan, Ariane Assele Kama, Christelle Bahlawane, Katy Beaumont, Nadia Beaupain, Lucrèce Beckers, Camille Bellora, Guy Berchem, Fay Betsou, Luc Biever, Dirk Brenner, Eleftheria Charalambous, Emilie Charpentier, Estelle Coibion, Sylvie Coito, Manuel Counson, Brian De Witt, Antonella Di Pasquale, Palma Di Pinto, Olivia Domingues, Claire Dording, Jean-Luc Dourson, Bianca Dragomir, Thibault Ferrandon, Ana Festas Lopes, Manon Gantenbein, Piotr Gawron, Laura Georges, Soumyabrata Ghosh, Stéphane Gidenne, Georges Gilson, Enrico Glaab, Clarissa Gomes, Borja Gomez Ramos, Valentin Groues, Wei Gu, Gael Hamot, Anne-Marie Hanff, Linda Hansen, Maxime Hansen, Lisa Hefele, Ahmed Hemedan, Estelle Henry, Margaux Henry, Sascha Herzinger, Laetitia Huiart, Alexander Hundt, Gilles Iserentant, Anne Kaysen, Fédéric Klein, Tommy Klein, Stéphanie Kler, Rejko Krüger, Pauline Lambert, Sabine Lehmann, Anja Leist, João Manuel Loureiro, Andrew Lumley, Annika Lutz, François Massart, Patrick May, Monica Marchese, Sophie Mériaux, Maura Minelli, Joel Mossong, Friedrich Mühlschlegel, Maeva Munsch, Mareike Neumann, Beatrice Nicolai, Markus Ollert, Claire Pauly, Laure Pauly, Lukas Pavelka, Joëlle Penny-Fritz, Magali Perguin, Achilleas Pexaras, Marie France Pirard, Jean-Marc Plesseria, Laurent Prévotat, Guilherme Ramos Meyers, Kavita Rege, Lucie Remark, Antonio Rodriguez, Kirsten Rump, Estelle Sandt, Bruno Santos, Venkata P. Satagopam, Aurélie Sausy, Christiane Schmitt, Margaux Schmitt, Reinhard Schneider, Valerie Schröder, Serge Schumacher, Alexandra Schweicher, Jean-Yves Servais, Florian Simon, Chantal Snoeck, Kate Sokolowska, Lara Stute, Stéphane Tholl, Noua Toukourou, Johanna Trouet, Christophe Trefois, Nguyen Trung, Jonathan Turner, Michel Vaillant, Carlos Vega Moreno, Charlène Verschueren, Claus Vögele, Maharshi Vyas, Xinhui Wang, Femke Wauters, Bernard Weber, Tania Zamboni

## Funding

The CON-VINCE Study is funded by the Research Fund Luxembourg (FNR; CON-VINCE) and the André Losch Foundation (Luxembourg).

## Additional Information:

ClinicalTrials.gov number, NCT04379297

## References

Bai, Y., Yao, L., Wei, T., Tian, F., Jiin, D.-Y., Chen, L., & Wang, M. (2020). Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA, 323(14), 1406–1407. https://doi.org/10.1056/NEJMoa2001316

Bernstein, D. P., Stein, J. A., Newcomb, M. D., Walker, E., Pogge, D., Ahluvalia, T., Stokes, J., Handelsman, L., Medrano, M., Desmond, D., & Zule, W. (2003). Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse and Neglect, 27(2), 169–190. https://doi.org/10.1016/S0145-2134(02)00541-0

Bogdan-Martin, D. (2019). Measuring digital development: Facts & figures 2019. https://news.itu.int/measuring-digital-development-facts-figures-2019/

Börsch-Supan, A., Brandt, M., Hunkler, C., Kneip, T., Korbmacher, J., Malter, F., Schaan, B., Stuck, S., & Zuber, S. (2013). Data Resource Profile: The Survey of Health, Ageing and Retirement in Europe (SHARE). International Journal of Epidemiology, 42(4), 992–1001. https://doi.org/10.1093/ije/dyt088

Börsch-Supran, A. (2019). Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 6. Release version: 7.0.0. SHARE-ERIC. Data set. 10.6103/SHARE.w6.700

Clarke, E., & Sherrill-Mix, S. (2017). ggbeeswarm: Categorical Scatter (Violin Point) Plots v 0.6.0. https://cran.r-project.org/package=ggbeeswarm

Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. Journal of Health and Social Behavior, 24(4), 385–396. https://doi.org/10.2307/2136404

Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brünink, S., Schneider, J., Luisa Schmidt, M., GJC Mulders, D., Haagmans, B. L., van der Veer, B., van den Brink, S., Wijsman, L., Goderski, G., Romette, J.-L., Ellis, J., Zambon, M., ... Chantal, R. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill, December, 1. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

Davies, W. (2016). Insights into rare diseases from social media surveys. Orphanet Journal of Rare Diseases, 11(1), 1–5. https://doi.org/10.1186/s13023-016-0532-x

Dijkman, R., Jebbink, M. F., Gaunt, E., Rossen, J. W. A., Templeton, K. E., Kuijpers, T. W., & van der Hoek, L. (2012). The dominance of human coronavirus OC43 and NL63 infections in infants. Journal of Clinical Virology, 53(2), 135–139. https://doi.org/10.1016/j.jcv.2011.11.011

Elwenspoek, M. M. C., Kuehn, A., Muller, C. P., & Turner, J. D. (2017). The effects of early life adversity on the immune system. Psychoneuroendocrinology, 82, 140–154. https://doi.org/10.1016/j.psyneuen.2017.05.012

Government of the Grand Duchy of Luxembourg. (2020). WEBSITE CORONAVIRUS (COVID-19). https://msan.gouvernement.lu/en/dossiers/2020/corona-virus.html

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., ... Zhu, S. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2002032

Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., Eiriksdottir, B., Fridriksdottir, R., Gardarsdottir, E. E., Georgsson, G., Gretarsdottir, O. S., Gudmundsson, K. R., Gunnarsdottir, T. R., Gylfason, A., Holm, H., ... Stefansson, K. (2020). Spread of SARS-CoV-2 in the Icelandic Population. New England Journal of Medicine, 1–14. https://doi.org/10.1056/nejmoa2006100

Heimdal, I., Moe, N., Krokstad, S., Christensen, A., Skanke, L. H., Nordbø, S. A., & Døllner, H. (2019). Human coronavirus in hospitalized children with respiratory tract infections: A 9-year population-based study from Norway. Journal of Infectious Diseases, 219(8), 1198–1206. https://doi.org/10.1093/infdis/jiy646

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Hughes, M. E., Waite, L. J., Hawkley, L. C., & Cacioppo, J. T. (2004). A short scale for measuring loneliness in large surveys: Results from two population-based studies. Research on Aging, 26(6), 655–672. https://doi.org/10.1177/0164027504268574

ISARIC (the International Severe Acute Respiratory and Emerging Infection Consortium). (n.d.). COVID-19 CRF. Retrieved May 5, 2020, from https://isaric.tghn.org/COVID-19-CRF/

Kassambara, A. (2020). ggpubr R Package: ggplot2-Based Publication Ready Plots v0.3.0. https://rpkgs.datanovia.com/ggpubr/

Kujawski, S. A., Wong, K. K., Collins, J. P., Epsetin, L., Killerby, M. E., Midgley, C. M., Abedi, G. R., Ahmen, N. S., & Almendares, O. (2020). Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nature Medicine, 2019. https://doi.org/10.1038/s41591-020-0877-5

Lai, C., Hung, Y., & Wang, C. (2020). Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of Microbiology, Immunology and Infection Xxx, January.

Li, N., Wang, X., & Lv, T. (2020). Prolonged SARS- CoV- 2 RNA shedding: Not a rare phenomenon. Journal of Medical Virology, jmv.25952. https://doi.org/10.1002/jmv.25952

Monto, A. S., DeJonge, P. M., Callear, A. P., Bazzi, L. A., Capriola, S. B., Malosh, R. E., Martin, E. T., & Petrie, J. G. (2020). Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of Households in Michigan. The Journal of Infectious Diseases, 1–8. https://doi.org/10.1093/infdis/jiaa161

Okba, N. M. A., Muller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., Bruin, E. de, Chandler, F. D., Yazdanpanah, Y., Hingrat, Q. Le, Descamps, D., Houhou-Fidouh, N., Reusken, C. B. E. M., Bosch, B.-J., Drosten, C., Koopmans, M. P. G., & Haagmans, B. L. (2020). SARS-CoV-2 specific antibody responses in COVID-19 patients. MedRxiv, 2020.03.18.20038059. https://doi.org/10.1101/2020.03.18.20038059

Ong, A. D., & Weiss, D. J. (2000). The impact of anonymity on responses to sensitive questions. Journal of Applied Social Psychology, 30(8), 1691–1708. https://doi.org/10.1111/j.1559-1816.2000.tb02462.x

Pan, Y., & Fond, M. (2014). Evaluating multilingual questionnaires: A sociolinguistic perspective. Survey Research Methods, 8(3), 181–194. https://doi.org/10.18148/srm/2014.v8i3.5483

R Core Team. (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.r-project.org/.

Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 385. https://doi.org/10.1063/1.4932809

Rammstedt, B., & John, O. P. (2007). Measuring personality in one minute or less: A 10-item short version of the Big Five Inventory in English and German. Journal of Research in Personality, 41(1), 203–212. https://doi.org/10.1016/j.jrp.2006.02.001

Rossman, H., Keshet, A., Shilo, S., Gavrieli, A., Bauman, T., Cohen, O., Shelly, E., Balicer, R., Geiger, B., Dor, Y., & Segal, E. (2020). A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys. Nature Medicine. https://doi.org/10.1038/s41591-020-0857-9

Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008). The brief resilience scale: Assessing the ability to bounce back. International Journal of Behavioral Medicine, 15(3), 194–200. https://doi.org/10.1080/10705500802222972

Spitzer RL, Kroenke K, Williams JW, & Löwe B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097.

Statec. (2020). 626,000 inhabitants as of January 1, 2020. https://statistiques.public.lu/en/news/population/population/2020/04/20200401/index.html

Streeck, H., Schulte, B., Kümmerer, B. M., Richter, E., Höller, T., Fuhrmann, C., Bartok, E., Dolscheid, R., Berger, M., Wessendorf, L., Eschbach-bludau, M., Kellings, A., Schwaiger, A., Coenen, M., Schmithausen, R. M., Schmid, M., & Hartmann, G. (2020). Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. https://www.ukbonn.de/C12582D3002FD21D/vwLookupDownloads/Streeck\_et\_al\_Infection\_fat ality\_rate\_of\_SARS\_CoV\_2\_infection2.pdf/\$FILE/Streeck\_et\_al\_Infection\_fatality\_rate\_of\_SAR S\_CoV\_2\_infection2.pdf/\$FILE/Streeck\_et\_al\_Infection\_fatality\_rate\_of\_SAR S\_CoV\_2\_infection2.pdf%0A

Turner, J. D., Ambrosio, C. D., Vögele, C., & Diewald, M. (2020). Twin Research in the Post-Genomic Era: Dissecting the Pathophysiological E ff ects of Adversity and the Social Environment. International Journal of Molecular Sciences Concept, 21, 1–18.


Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., Kuhn, M., Pedersen, T., Miller, E., Bache, S., Müller, K., Ooms, J., Robinson, D., Seidel, D., Spinu, V., ... Yutani, H. (2019). Welcome to the Tidyverse. Journal of Open Source Software, 4(43), 1686. https://doi.org/10.21105/joss.01686

Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Ehmann, R., Zwirglmaier, K., Drosten, C., & Wendtner, C. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature, 1–14. https://doi.org/10.1038/s41586-020-2196-x

World Health Organization (WHO). (2014). Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care. WHO Guidelines, 1–156. http://apps.who.int/iris/bitstream/10665/112656/1/9789241507134\_eng.pdf?ua=1


World Health Organization (WHO). (2020a). Coronavirus (COVID-19). https://covid19.who.int/

World Health Organization (WHO). (2020b). Coronavirus disease 2019 (COVID-19) Situation Report – 51. https://doi.org/10.1001/jama.2020.2633



**Figure 1:** Study design and testing. A representative sample of the Luxembourgish population was invited to join the study. Following the completion of an online questionnaire and biosampling, rRT-PCR and serology were performed. Asymptomatic and oligosymptomatic participants (either

positive or negative for the virus) were followed up on a bi-weekly basis for a total of 4 times. A final follow-up will take place after one year.



**Figure 2:** Data and sample flow in CON-VINCE cohort. Study participants are recruited by a survey company (TNS-IIres) based on a large representative panel of residents of Luxembourg. Participant personal data is securely collected and can only be accessed by the clinical study team. Each participant's personal record is assigned with a pseudonym. All data is collected by a protected web-based interface and transferred along with the pseudonym to the Data and Computing Platform hosted at the LCSB in a secure data center. Biosamples are collected at different sample collection hubs across Luxembourg and shipped to IBBL for sample processing and biobanking. Biosamples are analysed at the Laboratoire National de Santé (LNS) and the Luxembourg Institute of Health (LIH) and the analysis results together with biosample annotations and barcodes are recorded in REDCap. Within the Data and Computing Platform, the pseudonymized data and results from biological analyses from REDCap is accessed by the Data Integration and Analysis Platform (Ada) via an Application Programming Interface and integrated results with clinical data made available through its secure and access-controlled web-application.







Figure 3: Algorithm for swab testing by rRT-PCR and decision tree



**Figure 4**: Density plots of IgG (panel A) and IgA (panel B) OD ratios (log2 transformation) of patient sera collected in 2018-2019 (specificity cohort A, n=187), COVID-19 convalescent patients (sensitivity cohort B, n=37) and CON-VINCE participants (n= 1820). When measuring IgA antibodies, the maximum OD read-out was used for 11/37 COVID-19 convalescent patients for which saturation was reached (panel B, cohort B, Log2 OD ratios > 3.5). Dotted lines represent thresholds for categorizing samples into negative, intermediate and positive.



**Figure 5**: Distribution of IgA and IgG OD ratios (log2 transformation) from 1820 CON-VINCE participants. Dotted lines represent thresholds for categorizing samples into negative, intermediate and positive.



**Figure 6**: Course of the infection in Luxembourg until 5th May 2020 (Number of people COVID+ tested, in intensive care or death per day)

Features	Estimates
Gender ratio, f/m	1.04
Male, n (%)	911 (48.93)
Female, n (%)	949 (50.97)
Diverse, n (%)	2 (0.10)
<b>Age</b> , Mean ± SD (range) Distribution, n (%)	47 ± 15 (18 yr – 84 yr)
18-29 yr	260 (13.96)
30-39 yr	370 (19.87)
40-49 yr	402 (21.59)
50-59 yr	376 (20.19)
60-69 yr	284 (15.25)
70-79 yr	158 (8.49)
80-89 yr	12 (0.64)
Education, Mean ± SD (range)	14 ± 4 (0 − 27 yr)
Household, n (%)	
1 person	236 (12.67)
2 persons	670 (35.98)
3 persons	380 (20.41)
4 persons	396 (21.27)
5 persons or more	180 (9.67)
<b>Geographical location</b> Distribution, n (%)	
Center	659 (35.39)
Est	243 (13.05)
North	290 (15.57)
Sud	670 (35.98)

#### Table 1: Population features of the 1862 participants

Table 2: Sensitivity of Euroimmun IgA and IgG ELISAs and combined IgA and IgG interpretation

Delay after symptom onset	No. of pos*/total No. of samples in this category (sensitivity in %)						
	lgA	lgG	IgA and IgG	IgA and/or IgG			
> 5 days	27/33 (81.8)	23/33 (69.7)	21/33 (63.6)	29/33 (87.9)			
> 10 days	22/25 (88.0)	21/25 (84.0)	19/25 (76.0)	24/25 (96.0)			
> 15 days	13/14 (92.9)	12/14 (85.7)	12/14 (85.7)	13/14 (92.9)			

\* Sera with intermediate results were considered positive

 Table 3: Proportions of participants with detectable anti-SARS-CoV-2 IgA and IgG antibody response

IgG status	No. of sera with a	No. of sera with a given IgA status according to the IgG status (%)						
	IgA negative	IgA positive	Total					
IgG negative	1614 (88.7)	171 (9.4)	1785 (98.1)					
IgG positive	5 (0.3)	30 (1.6)	35 (1.9)					
Total	1619 (89.0)	201 (11.0)	1820 (100.0)					

**Table 4**: Overview of combined rRT-PCR results and antibody response for six participants with initial single gene-positive rRT-PCR outcome

Participant (P)	of first	No. of replicates detected by confirmatory rRT-PCRs (Mean Ct value) <sup>b</sup>		RT-PCR consensus result at v0	RT-PCR results 48h after v0	Serology results		
		In house E gene	In house N gene	FTD			IgA OD ratio (interpretation)	IgG OD ratio (interpretation)
P1	36.00	1/2 (37.36)	2/2 (36.09)	2/2 (36.89)	Positive	n.a.	1.0 (Intermediate)	0.9 (Intermediate)
P2	35.10	1/2 (36.16)	2/2 (35.42)	2/2 (36.65)	Positive	Negative	4.0 (Positive)	5.3 (Positive)
P3	35.80	1/2 (35.33)	2/2 (36.59)	1/2 (39.51)	Positive	Negative	10.1 (Positive)	11.3 (Positive)
P4	34.15	2/2 (35.12)	2/2 (34.88)	2/2 (35.18)	Positive	n.a.	5.8 (Positive)	7.2 (Positive)
P5	35.77	0/2	0/2	0/2	Currently negative	n.a.	0.4 (Negative)	0.2 (Negative)
P6	36.6	1/2 (36.63)	2/2 (35.30)	2/2 (37.30)	Positive	n.a.	5.4 (Positive)	8.2 (Positive)

<sup>a</sup> All inconclusive samples were negative in Allplex 2019-nCoV Assay E gene and RdRp gene targets, but positive in N gene.

<sup>b</sup> Confirmatory testing was done by in house generic rRT-PCR assays for the E gene and N gene targets and in addition by the FTD SARS-CoV-2 assay using N gene and ORF1ab targets.

**Table 5**: Overview of self-reported symptoms and self-reported possible source ofSARS-CoV-2 exposure in the last 14 days prior to enrolment for six study participantswith initial single gene-positive rRT-PCR outcome

Participant	Self-reported symptoms	Self-reported possible source of exposure to SARS-CoV-2
P1	fatigue or malaise, headache	none
P2	cough, runny nose, pink eye	travel history documented COVID-19 cases
P3	cough	contact with COVID-19 household member
P4	fatigue or malaise, headache	none
P5	none	none
P6	none	contact with COVID-19 household member

**Table 6**: Overview of contact (any and with COVID-19 cases), travel history to regions with documented COVID-19 circulation, reported comorbidities and self-reported symptoms in the last 14 days in IgG seropositive participants (n=35)

Age class	Previously tested for SARS- CoV-2 (outcome)	rRT-PCR status at baseline	lgA sta tus	Trav el hist ory	Any contact outside househol d	Home office or work on site	Contact with a confirmed or probable case (No. Of COVID-19	Documented COVID-19 positive case in the household	Com orbi ditie s	Total No. Of sympto ms	Symptoms in the past 14 days
30-39	Yes (P)	Negative	Р	No	n.r.		Yes	Yes	No	3	runny nose, wheezing, muscle aches,
20-29	Yes (P)	Negative	Р	No	n.r.		No	n.r.	No	3	cough, runny nose, headaches
50-59	Yes (P)	Negative	Р	No	No		Yes	Yes	Yes	2	muscle aches, joint pain
40-49	Yes (P)	Negative	Ρ	No	No	home office	Yes	Yes	No	8	cough, runny nose, shortness of breath, joint pain, fatigue or malaise, headaches, diarrhoea, loss of smell
60-69	Yes (P)	Positive	Ρ	No	No		Yes	Yes	Yes	1	cough
40-49	Yes (P)	Negative	Ρ	No	No	home office	Yes	Yes	No	13	fever, sore throat, shortness of breath, wheezing, chest pain, muscle aches, joint pain, fatigue or malaise, headaches, abdominal pain, vomited or nausea or vertigo, diarrhoea, loss of smell
20-29	Yes (P)	Negative	Ρ	No	No		Yes	Yes	No	10	flu-like symptoms, cough, productive cough, runny nose, shortness of breath, headaches, vomited or nausea or vertigo, diarrhoea, pink eye, ear pain
20-29	Yes (P)	Negative	Ρ	No	n.r.		Unknown	n.r.	Yes	5	fatigue or malaise, headaches, diarrhoea, loss of smell, ear pain
50-59	Yes (P)	Negative	Ρ	No	n.r.	home office and on site	Yes	Yes	Yes	0	
50-59	Yes (P)	Negative	Р	No	Yes	on site	Yes	Yes	Yes	1	shortness of breath
30-39	Yes (P)	Negative	Ρ	No	n.r.		Yes	Yes	No	4	runny nose, headaches, altered consciousness or confusion, unusual skin rash
20-29	Yes (N)	Negative	Р	No	n.r.	home office	No	n.r.	No	2	headaches, unusual skin rash
30-39	Yes (N)	Negative	Ν	No	n.r.	on site	No	n.r.	No	8	sore throat, runny nose , chest pain, muscle aches, joint pain headaches , vomited or nausea or vertigo, diarrhoea
20-29	Yes (N)	Negative	Ρ	No	No	home office	Yes	Yes	No	6	cough, runny nose, wheezing, muscle aches, fatigue or malaise, diarrhoea
60-69	Yes (N)	Negative	Р	No	n.r.		No	n.r.	No	4	flu-like symptoms, cough, sore throat, chest pain
70-79	Yes (N)	Negative	Ν	No	n.r.		No	n.r.	Yes	9	sore throat, shortness of breath, chest pain, joint pain, fatigue or malaise, headaches abdominal pain, pink eye, ear pain,
30-39	No	Positive	Р	No	n.r.	on site	No	n.r.	No	2	fatigue or malaise, headaches
60-69	No	Negative	Ν	No	n.r.		No	n.r.	No	0	
40-49	No	Negative	Ρ	No	n.r.	home office	No	n.r.	No	6	flu-like symptoms, cough, sore throat, runny nose, muscle aches, headaches

20-29	No	Negative	Ρ	No	n.r.		No	n.r.	No	0	
30-39	No	Negative	Ρ	No	Yes	home office	Yes	n.r.	No	7	cough, sore throat, runny nose, chest pain, headaches, vomited or nausea or vertigo, ear pain
30-39	No	Negative	Р	No	n.r.	home office	No	n.r.	No	0	
30-39	No	Negative	Ρ	No	n.r.	on site	No	n.r.	No	2	headaches, loss of smell
30-39	No	Negative	Ρ	No	n.r.	home office	No	n.r.	No	0	
30-39	No	Positive	Р	Yes	n.r.	on site	Unknown	n.r.	No	3	cough, runny nose, pink eye
60-69	No	Negative	Ρ	No	n.r.		No	n.r.	No	3	cough, productive cough, loss of smell
40-49	No	Negative	Р	No	n.r.	home office	No	n.r.	No	0	
60-69	No	Negative	Ν	No	n.r.		No	n.r.	No	0	
50-59	No	Negative	Р	No	n.r.	home office	No	n.r.	No	0	
40-49	No	Negative	Р	No	n.r.	home office	No	n.r.	No	0	
50-59	No	Negative	Р	No	Yes	on site	Yes	n.r.	No	1	chest pain
50-59	No	Negative	Ν	No	n.r.		No	n.r.	No	5	sore throat, runny nose, shortness of breath joint pain, pink eye
20-29	No	Negative	Р	No	n.r.	home office	Unknown	n.r.	Yes	1	runny nose
50-59	No	Positive	Ρ	No	n.r.	home office	No	n.r.	Yes	2	fatigue or malaise, headaches
70-79	No	Positive	Ρ	No	n.r.		Yes	Yes	Yes	0	


n.r. not reported

 Table 7: Prevalence estimates with weights calculated with gender, 10 years age categories and electoral district

			95%		
Positivity	Frequency	Estimate (%)	Lower Limit (%)	Upper Limit (%)	Design Effect
RT PCR	5/1830	0.2973	0.0298	0.5649	1.1478
IgA	200/1807	11.073	9.5404	12.6057	1.1199
lgG	35/1807	2.0947	1.3683	2.8212	1.2082
Infection rate (IR)	35/1835	2.0586	1.3446	2.7726	1.2055

# **Supplementary Figures :**

#### **Supplementary Figure 1**



**Supplementary Figure 1:** Number of household members (including the participant) for participants tested IgG positive compared to participants tested RT-PCR and IgG negative (All Negatives).

#### Supplementary Table 1: Biosample collection, processing and storage

Biosample	Primary Container	Process	Derivative	Aliquoting Scheme	Storage Conditions
Nasal Swab Oropharyngeal	Dual Swab collection in 2ml Universal	Swab/UTM aliquoting	Swab/ UTM	200 µl x 1 1.2 ml x 1	-80°C
Swab	Transport Medium (UTM)	RNA extraction	RNA	100 µl x 1	-80°C
Blood	10 ml CAT tube	Serum aliquoting	Serum	400 µl x 6	-80°C
	10 ml EDTA tube	Plasma aliquoting	Plasma EDTA	400 µl x 6	-80°C
		Buffy coat aliquoting	Buffy Coat	450 µl x 2	-80°C
Stool	Zymo DNA/RNA Shield Collection Tube	Stool aliquoting	Stool	500 µl x 4	-80°C
			Stool	3.8 ml x 1	-80°C

**Supplementary table 2**: Prevalence estimates with weights calculated with gender, 10 years age categories and canton

			95%		
Positivity	Frequency	Estimate (%)	Lower Limit (%)	Upper Limit (%)	Design Effect
RT PCR	5/1830	0.3282	0.0208	0.6355	1.373
IgA	200/1807	10.7013	9.1691	12.2335	1.1533
IgG	35/1807	1.9705	1.2519	2.6891	1.255
IR	35/1835	1.9391	1.2316	2.6466	1.2551

Adapted from Sprint Sari Case Report Form by ISARIC. Used and made available by ISARIC under CC BY SA 4.0

PARTICIPANT IDENTIFICATION #: [\_\_\_][\_\_\_]--- [\_\_\_][\_\_\_][\_\_\_]

NOVEL CORONAVIRUS (nCoV) (Centre-ID)

(Participant ID)

**CON-VINCE Study** – Electronic Case Record Form

(full extended part with defined minimal data set)

# **EXCLUSION CRITERIA**

Infection by Coronavirus with severe disease course requiring a hospital admission prior to the inclusion to the study.

🗆 Yes 🗆 No

Presence of fever and respiratory distress/cough at the time of inclusion not attributable to other known chronic disease.

□ Yes □ No

**Explanatory note for participant:** The virus called SARS-CoV-2 (further indicated as Coronavirus) is the cause of the current pandemic disease known as COVID-19. It is a rapidly spreading virus affecting mainly the respiratory tract having up to 80% an asymptomatic course (meaning without any symptoms) or very mild upper-respiratory disease with runny nose or pink eye. However, in a fraction of patients, the disease evolves to fever and cough with or without respiratory distress and in some cases, a hospitalisation with therapy by inhaled oxygen and further medical support is needed.

# (Minimal Data set) Coronavirus STATUS

#### Have you already been tested for Coronavirus?\*

□ Yes □ No

*If yes:* When have you been tested for Coronavirus?

 $[_D_{-}]_{-}M_{-}]_{-}M_{-}/[_2_{-}]_{-}V_{-}]_{-}V_{-}$ 

If yes: What was the result of your Coronavirus test?

Positive
 INegative
 Unknown

\* Replaced by the following question for the Follow-ups:

Since your visit to the lab for this study, have you been tested for Coronavirus? [outside the context of this study]

	(Minimal Data set) EPIDEMIOLOGICAL FACTORS				
In the la	•	e you travelled t	o a foreign country with documented cases of Coronavirus		
	□ Yes	□ No			
lf Yes: <b>How m</b>	any countries di	id you travel to? <sup>?</sup>	2		
	Please specify:				
		ollowing element nfection in the la	ts for each of your visits to a foreign country with documented ast 14 days. <sup>2</sup>		

If you visited more than 5 countries, please refer to 5 most recent ones.

TRAVEL DOCUM	ENTATION:	
Country: City/Geographic a Return Date (DD/I	rea:	
Country: City/Geographic a Return Date (DD/I	rea:	
Country: City/Geographic a Return Date (DD/I	rea:	
Country: City/Geographic a Return Date (DD/I	rea:	

In the last 14 days, have you been in close contact with a confirmed or probable case of Coronavirus infection, while that patient was either asymptomatic (having no symptoms such as fever/cough) or symptomatic (having symptoms such as fever, cough or respiratory distress)?

□ Yes □ No □ Unknown

Close contact is defined as:

- Health care associated exposure, including providing direct care for novel coronavirus patients, e.g. health care worker, working with health care workers infected with novel coronavirus, visiting patients or staying in the same close environment of a novel coronavirus patient, or direct exposure to body fluids or specimens including aerosols.

- Working together in close proximity or sharing the same classroom environment with a novel coronavirus patient.

- Traveling together with novel coronavirus patient in any kind of conveyance.

- Living in the same household as a novel coronavirus patient.

If Yes:

Who was the person infected with Coronavirus (or believed to be infected) you have come to contact?

Household member
Family member who does not live at home
Close neighbor
Friend
Co-worker
$\Box$ Cleaning staff, caregiver, household services, or similar
□ Coronavirus + patient (in the case of health personnel)
Professional client, customer
□ Public sector worker (e.g. cashier, bus driver, etc.)
□ Other contacts
Don't know

# In the last 14 days, have you been present in a healthcare facility where Coronavirus infections are managed?

□ Yes □ No □ Unknown

In the last 14 days, have you been present in a laboratory handling suspected or confirmed Coronavirus samples?

□ Yes □ No □ Unknown

# (Minimal Data set) DEMOGRAPHICS

#### Please insert in the data file the date of the interview.

[\_D\_][\_D\_]/[\_M\_][\_M\_]/[\_2\_][\_0\_][\_Y\_][\_Y\_]

What is your nationality? If you have dual or multiple nationalities, please don't hesitate to indicate them at the next Question.

Please specify (list of nationalities): \_\_\_\_\_

#### Do you have dual or multiple nationalities?

□ Yes □ No

If yes:

#### Please indicate your second nationality.

Please specify (list of nationalities):

#### What is your country of origin?

Please specify (list of countries): \_\_\_\_\_

#### Country of current residence = Luxembourg

#### In which municipality do you live?

Please specify (list of municipalities in Luxembourg):

#### Please indicate your zip code.

Please specify: L- \_\_\_\_ Unknown

#### What is your gender at birth?

□ Male □ Female □ P

# □ Prefer not to say □ Diverse

#### Please indicate your current age in years.

Years: \_\_\_\_\_

#### What is your current marital status?

	, children ao y	you have?	author/funder, who has granted medRxiv a license to display the preprint in perpetuity reserved. No reuse allowed without permission.
P	lease specify: _		□ No children
How many	/ grandchildre	en do you have?	?
P	lease specify: _		□ No grandchildren
-	female respon regnant at the		
	Yes	□ No	
lf Yes: Please ind	licate at which	n gestational we	eek you are pregnant.
W	/eek:		
Have you	given birth in	the last 6 mont	hs?
	Yes	□ No	□ No answer
lf Yes: Please ind	licate the preg	gnancy outcom	e.
	Live birth	□ Still birth	□ No answer
If Livebirth. Please ind	icate the deliv	very date.	
[_	_D_][_D_]/[_M_	][_M_]/[_2_][_0_	][_Y_][_Y_]
lf Livebirth. Has your l		ted for Corona	virus?
	Vee	□ No	□ No answer
	Yes		
If Yes:		he Coronavirus	s-test?

# (Minimal Data set) EDUCATION / PROFESSIONAL BACKGROUND

#### What is your educational degree?

Please choose the highest degree achieved.

- □ No formal degree
- □ Fundamental Education
- Secondary Education Classical system
- □ Secondary Education Technical system
- □ University degree: Bachelor
- □ University degree: Master or above
- Other type of degree, please specify: \_\_\_\_\_

### How many years of schooling have you successfully accomplished?

Please indicate in years [kindergarten not counted, and PhD counts as maximum 3 years]

Years:

#### What is your current employment status<sup>1</sup>?

- □ Full-time employed
- □ Part-time employed
- □ Self-employed or working for own family business
- □ Unemployed
- □ In vocational training/retraining/education
- □ Parental leave
- □ In retirement or early retirement
- □ Permanently sick or disabled
- □ Looking after home or family
- □ Other, please specify: \_\_\_\_\_

Filter: Full-time employed, part-time employed, self-employed or working for own family business, parental leave What is your current professional activity?

Please specify: \_\_\_\_\_

#### In which field do you work?

- Essential services (e.g. police, firefighter)
- □ Wholesale / retail trade
- □ Manufacturing industry
- □ Health and social services activities \*\*
- □ Hospitality
- □ Education
- Public administration and defense
- □ Construction
- □ Transport and storage
- □ Administrative activities and auxiliary services
- Professional, scientific and technical activities
- □ Agriculture, livestock, forestry and fishing

- Domestic staff
- Financial and insurance activities
- Artistic, recreational and entertainment activities
- Sanitation, waste management and decontamination activities\*\*
- Other services, please specify: \_

```
Link ** to this question:
```

```
Are you employed as a Healthcare Worker?
```

□ Yes □ No □ Unknown

If Yes:

### More specifically, what is your profession?

- Nurse
- Physician
- Pharmacist
- Physiotherapist
- **Occupational Therapist**
- Psychologist
- Dietician
- Secretary in healthcare
- Cleaning staff in hospital/healthcare
- Technician
- Other profession, please specify: \_

Link \*\* to this question:

### Are you employed in a microbiology laboratory?

□ Yes □ No

If Yes:

Have you been in contact with suspected COVID-19 positive samples?

□ Yes □ No

# (Extended part) HOME AND SOCIAL CONTACT / SOCIO-ECONOMIC STATUS

#### What is the type of your household?

- П House
- Apartment
- Nursing home
- Residence for the disabled
- Jail
- Hotel
- Another type of shared residence (monastery, etc.)
- Homeless
- If none of the above, please specify: \_

#### How many people live in your household (including yourself)?

□ 1 □ 4 □ 2 □ 3 □ 5 or more

# What is the age of household members (including yourself)? Please type in the number of the household members to the appropriate age categories.

If a category doesn't apply, please indicate 0.

Number of 0 - 4 years old	[]
Number of 5 - 9 years old	[]
Number of 10 - 14 years old	[]
Number of 15 - 19 years old	[]
Number of 20 - 29 years old	[]
Number of 30 - 39 years old	[]
Number of 40 - 49 years old	[]
Number of 50 - 59 years old	[]
Number of 60 - 69 years old	[]
Number of 70 - 79 years old	[]
Number of 80+ years	[]

#### Is one of your household member coronavirus positive?<sup>1</sup>

□ No

□ Yes

□ Unknown (not tested)

If Yes:

What is the age of household members (yourself included) that have been tested coronavirus positive? Please type in the number of the household members to the appropriate age categories.<sup>1</sup> If a category doesn't apply, please indicate 0.

Number of 0 - 4 years old	[]
Number of 5 - 9 years old	[]
Number of 10 - 14 years old	[]
Number of 15 - 19 years old	[]
Number of 20 - 29 years old	[]
Number of 30 - 39 years old	[]
Number of 40 - 49 years old	[]
Number of 50 - 59 years old	[]
Number of 60 - 69 years old	[]
Number of 70 - 79 years old	[]
Number of 80+ years	[]

#### Do you own the home you live in?

□ Yes □ No

#### What is your household gross annual income?

- □ 0 25 000 Euros
- □ 25 000 50 000 Euros
- □ 50 000 75 000 Euros
- □ 75 000 100 000 Euros
- □ 100 000 150 000 Euros
- □ More than 150 000 Euros
- □ No answer

#### Are you in self-isolation / self-quarantine?<sup>1</sup>

□ Yes □ No

If Yes:

Since when are you in self-isolation / self-quarantine?<sup>1</sup> Please indicate the date.

### $[_D_{-}][_D_{-}]/[_M_{-}][_M_{-}]/[_2_{-}][_V_{-}]$

Filter: Ask only if: Full-time employed, part-time employed, self-employed or working for own family business, parental leave, self-isolation/self-quarantine = No

Are you still traveling to work?<sup>1</sup>

□ Yes □ No

If Yes:

With how many people do you currently share your office/workplace?<sup>1</sup>

□ I work alone at the office

- □ 1-2
- □ 3-5
- □ 6 or more

Filter: Ask only if: Full-time employed, part-time employed, self-employed or working for own family business, parental leave **Are you doing home-office?**<sup>1</sup>

□ Yes □ No

If Yes: Since when are you doing home-office?<sup>1</sup> Please indicate the date.

[\_D\_][\_D\_]/[\_M\_][\_M\_]/[\_2\_][\_0\_][\_Y\_][\_Y\_]

□ I'm always doing home office

# (Minimal Data Set) MAJOR LIFE EVENTS

Turner, J. D., Ambrosio, C. D., Vögele, C., & Diewald, M. (2020). Twin Research in the Post-Genomic Era: Dissecting the Pathophysiological Effects of Adversity and the Social Environment. *International Journal of Molecular Sciences*, *21*, 1–18.

		(Min	imal Data set) COMOR	BIDITIES	
lease	e indicate you	r current height (	in cm)?		
	Please spec	cify:			
Please	e indicate you	r current weight	(in kg)?		
	Please spec	;ify:			
-	-		disease (meaning chronic he ure/hypertension <b>)?</b>	art failure includ	ling inborn heart disease, but
	□ Yes	□ No	Unknown		
Are yo stent)?	•	a cardiovascula	r disease (e.g. heart infarction	n, Angina pectol	ris, placement of coronary
	🗆 Yes, plea	se specify:		□ No	
-	ou affected by pertensive med		eaning: chronic elevated Bloc	od pressure ovel	r 140/90 or treatment by
	□ Yes	□ No	Unknown		
If Yes:					
	u take any ant	ihypertensives?			
	-		ne of the antihypertensives: _		🗆 No
Do yo Are yo	□ Yes, plea	se specify the nar	ary disease (chronic inflamm		
Do yo Are yo	□ Yes, plea <b>Du affected by</b> nary disease be	se specify the nar chronic pulmon ut without includin	ary disease (chronic inflamm		
<b>Do yo</b> <b>Are yo</b> oulmol	□ Yes, plea <b>Du affected by</b> nary disease bi □ Yes, plea	se specify the nar <b>chronic pulmon</b> <i>ut without includin</i> se specify:	<b>ary disease</b> (chronic inflamm g asthma) <b>?</b>	atory lung disea	se- e.g. chronic obstructive
<b>Do yo</b> <b>Are yo</b> pulmol	□ Yes, plea <b>Du affected by</b> nary disease bi □ Yes, plea	se specify the nar <b>chronic pulmon</b> <i>ut without includin</i> se specify:	<b>ary disease</b> (chronic inflamm g asthma) <b>?</b>	atory lung disea	se- e.g. chronic obstructive
Do yo Are yo pulmo Are yo	□ Yes, plea ou affected by nary disease bi □ Yes, plea ou affected by □ Yes	se specify the nar <i>chronic pulmon</i> <i>ut without includin</i> se specify: asthma (official c	ary disease (chronic inflamm g asthma)? liagnosis by a physician)?	atory lung disea	se- e.g. chronic obstructive
Do yo Are yo oulmo	□ Yes, plea ou affected by nary disease bi □ Yes, plea ou affected by □ Yes	se specify the nar <i>chronic pulmon</i> <i>ut without includin</i> se specify: asthma (official of □ No	ary disease (chronic inflamm g asthma)? liagnosis by a physician)?	atory lung disea	se- e.g. chronic obstructive
Are yo bulmo Are yo Do yo If Yes: Do yo	<ul> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes</li> </ul>	se specify the nar <i>chronic pulmon</i> <i>ut without includin</i> se specify: <b>asthma</b> (official of □ No <b>be of Diabetes?</b> □ No <b>conic diabetes-re</b>	ary disease (chronic inflamm g asthma)? liagnosis by a physician)?	atory lung disea □ No	se- e.g. chronic obstructive □ Unknown
Are yo oulmo Are yo Do yo If Yes: Do yo	<ul> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes</li> </ul>	se specify the nar <i>chronic pulmon</i> <i>ut without includin</i> se specify: <b>asthma</b> (official of □ No <b>be of Diabetes?</b> □ No <b>conic diabetes-re</b>	ary disease (chronic inflamm g asthma)? liagnosis by a physician)? □ Unknown	atory lung disea □ No	se- e.g. chronic obstructive □ Unknown
Do you pulmon Are you Do you If Yes: Do you the chi	<ul> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes, please</li> <li>□ Yes</li> </ul>	se specify the nar chronic pulmon ut without includin se specify: asthma (official of □ No be of Diabetes? □ No ronic diabetes-re ? □ No	ary disease (chronic inflamm g asthma)? liagnosis by a physician)? Unknown Unknown	atory lung disea □ No	se- e.g. chronic obstructive

nedRxiv preprint (which was not	doi: https://doi.o t certified by pe	org/10.1101/20 er review) is the All righ	20.05.11.20092916; this vers e author/funder, who has gran tts reserved. No reuse allowe	ion posted May 18, 20 nted medRxiv a license d without permission.	20. The copyright holder for this preprint e to display the preprint in perpetuity.
lf Yes: <b>Are you on</b> (	dialysis?				
□ Y	′es	□ No	Unknown		
-		-	<b>disorder</b> (meaning: inflam ly the joints, but also som		the connecting or supporting ligaments, bones, and
□ Y	′es, please sp	ecify:		□ No	Unknown
Are you affe	ected by a mo	oderate or se	evere liver disease (chror	nic liver dysfunction	of any cause) <b>?</b>
□ Y	′es	□ No	Unknown		
Have you be	een diagnose	d with deme	ntia (e.g. Alzheimer disea	ise, vascular demer	tia, Lewy Body dementia)?
□ Y	′es, please sp	ecify:		□ No	Unknown
Have you ha	ad a stroke?				
□ Y	′es	□ No	Unknown		
Are you affe	ected by a mi	ld liver disea	ase (chronic liver dysfunct	ion of any cause dia	ngnosed by a physician)?
□ Y	′es, please sp	ecify:		□ No	Unknown
Do you suff	er from maln	utrition?			
□ Y	′es	□ No	Unknown		
Are you affe disorders)?	ected by a ch	ronic neurol	ogical disorder (e.g. mul	tiple sclerosis, epile <sub>i</sub>	psy, neuromuscular
□ Y	′es, please sp	ecify:		□ No	Unknown
Are you affe	ected by a ne	urodegenera	ative disease (e.g. Parkin	son's Disease) <b>?</b>	
□ Y	′es, please sp	ecify:		□ No	Unknown
Have you be	een diagnose	ed with any fo	orm of cancer (malignant	neoplasm)?	
□ Y	′es, please sp	ecify which ty	/pe:	□ No	Unknown
Have you be	een diagnose	d with Chro	nic hematologic disease	(e.g. lymphoma, le	ukemia, multiple myeloma)?
□ Y	′es, please sp	ecify:		□ No	Unknown
Have you be	een diagnose	d positive fo	or virus HIV (AIDS)?		
□ Y	′es	□ No	Unknown		
-	ected by an a upus erythem		disease (e.g. autoimmune	e thyroiditis-Hashimo	oto disease, Sjögren
□ Y	′es, please sp	ecify:		□ No	Unknown

medRxiv pre (which wa	print doi: https://doi. as not certified by pe	org/10.1101/2020.05.11.2009 er review) is the author/funder All rights reserved. N	2916; this version po r, who has granted m lo reuse allowed with	sted May 18, 2 edRxiv a licen out permission	2020. The copyright holder for this preprint se to display the preprint in perpetuity.
Have yo	ou undergone an	organ transplantation?			
	□ Yes, please s	pecify which organ:		□ No	Unknown
-	on any treatment nune disease or cl	nt suppressing your imm nemotherapy)?	<b>une system</b> (e.g. i	mmunosupp	ressive therapy for an
	□ Yes, please s	pecify:		□ No	Unknown
Do you	suffer from any	psychiatric disease (e.g.	depression, schizo	phrenia, bipc	olar disease)?
	□ Yes, please s	pecify:		□ No	Unknown
Are you	affected by any	other relevant disease ne	ot addressed befo	ore?	
	□ Yes, please s	pecify:		□ No	
Do you	exercise <u>during</u>	the Coronavirus pandem	lic? <sup>1</sup>		
	□ Yes	□ No			
	-	eek do you exercise durin category doesn't apply to you,	•	s pandemic	? <sup>1</sup>
	Hours inside:				
	Hours outside:				
Did you	exercise before	the measures implement	ted in response to	o the corona	virus pandemic?
	□ Yes	□ No			
		ek do you exercise befor category doesn't apply to you,		s pandemic <sup>4</sup>	?
	Hours inside: Hours outside:				
Do you	currently smoke	?			
	□ Yes				
	□ No, but I am a	former smoker			
	□ No and I neve				

□ No, but I live with someone who smokes

# (Minimal Data set) CURRENT MEDICATION

#### Do you take medication on a regular basis?

□ Yes □ No

If Yes:

How many different medications do you take on a regular basis?

Please indicate a number: \_\_\_\_\_

# Please document the following elements for every medication you take on a regular basis.

NAME (e.g. Asaflow)	<b>DOSE</b> (e.g. 100 mg)	DOSING INTERVALS (e.g. 1x/day)	<b>SINCE WHEN?</b> (e.g. 2018)

# (Minimal Data set) RESPIRATORY SYMPTOMS ONSET

Do you currently have flu-like symptoms (e.g. fever, cough, runny nose, pink eye)?

□ Yes □ No □ Unknown

If Yes:

When did the first/earliest flu-like symptom(s) occur?

Please indicate the date.

[\_D\_][\_D\_]/[\_M\_][\_M\_]/[\_2\_][\_0\_][\_Y\_][\_Y\_]

Do you take any anti-inflammatory medication or any medication to reduce fever or pain (e.g. lbuprofen, paracetamol, aspirin or other)?

□ Yes, please specify: \_\_\_\_\_ □ No □ Unknown

Signs and symptoms (initial symptoms) (observed/reported by participant and associated with this episode of acute illness, meaning the occurrence of the symptoms in the recent 14 days)

In the last 14 days, have you ...

	Yes	No	Unknown
had a fever			
coughed If yes: Have you coughed with mucus production? If yes: Did the mucus contain blood?			
noticed a rapid loss of smell and/or taste			
had a sore throat			
had a runny nose			
had an Ear pain			
noticed wheezing while breathing			
experienced chest pain			
had muscle aches			
had joint pain			
experienced a sudden increase in Fatigue / Malaise			
suffered from shortness of breath at rest or during mild body exertion			

All rights rese	Yes	No	Unknown
had headaches			
or someone close to you noticed an altered consciousness/confusion			
had any rhythmic cramps (meaning epileptic seizures)			
experienced abdominal pain			
vomited/suffered from nausea or vertigo			
had diarrhea			
had pink eyes (conjunctivitis=inflammation the eyes)			
noticed any unusual skin rash			
noticed any lymphatic glands to be swollen			
had any bleeding <i>If yes:</i> Please specify the site(s) of the bleeding(s) you have had in the last 14 days. Please specify:			

# (Extended part) ENVIRONMENTAL CONDITIONS AT HOME WITH A DIAGNOSIS OF COVID-19

Filter: Asked only if COVID positive OR if living with a COVID positive household member<sup>3</sup>

#### Do you currently dispose of ...?

	Yes	No	Unknown
a separate room for the patient			
the necessary medication			
food			
masks for the patient			
masks for the family members providing care			
gloves			
hand hygiene products			
of a caregiver			
access to medical advice and care			

#### Is there currently a person at risk living at your home?

A person at risk is defined either by age (over 60) and/or being affected by coronary heart disease/ hypertension/ diabetes/ chronic pulmonary disease and/ or having compromised immune system by an immuno-suppressive therapy or due to an immuno-compromising disease.

□ Yes □ No □ Unknown

# (Extended part) BEHAVIOR ANALYSIS DURING CORONAVIRUS - PANDEMIC / COMPLIANCE TO THE NATIONAL GUIDELINES

Are you familiar with the recommendations and restrictions issued by the government in Luxembourg?

□ Yes □ No

#### To what extent do you agree with the following statements?

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
I have tried my best to follow these recommendations					
I followed the general hygiene recommendations (handwashing, sneezing in elbow/fresh tissue, avoiding to touch my face)					
I followed the general social distancing recommendations (avoiding handshaking, keeping 2m distance, staying home, avoid traveling)					
Coronavirus is a major public health concern					

#### How often did you leave the house during the last week?

If you didn't leave the house during the last week, please indicate 0.

 Please indicate in days:

 Unknown

 How often did you leave the house during an average week before the coronavirus pandemic?<sup>2</sup>

 If you didn't leave the house during the last week, please indicate 0.

 Please indicate in days:

 Unknown

 Do you drink alcohol?

 Yes

 No

 How many units of alcohol did you drink during the last week?

 Hereby a few examples of 1 unit: Large shots of spirit (35ml); Bottle of beer (330ml); Standard glass of wine (175ml)

 Please specify:

 Unknown

How many units of alcohol did you drink <u>during an average week (before the Coronavirus pandemic)</u>?<sup>2</sup> Hereby a few examples of 1 unit: Large shots of spirit (35ml); Bottle of beer (330ml); Standard glass of wine (175ml)

Please specify: \_\_\_\_\_

🗆 Unknown

surfing the internet?	hours/day
on social media platforms (e.g., Facebook, Instagram, Twitter)?	hours/day
watching news on television?	hours/day
speaking with friends or family (via telephone, video calls etc.)?	hours/day
on streaming platforms (e.g., Netflix, Youtube)?	hours/day

# (Extended Part) PSYCHOLOGICAL QUESTIONNAIRES

# Center for Epidemiologic Studies Depression Scale (CES-D Scale)

Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. *Applied psychological measurement*, *1*(3), 385-401.

# Generalized Anxiety Disorder 7-item (GAD-7) scale

Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. *Archives of internal medicine*, *166*(10), 1092-1097. Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008).

# UCLA Loneliness Scale-short version

Hughes, M. E., Waite, L. J., Hawkley, L. C., & Cacioppo, J. T. (2004). A short scale for measuring loneliness in large surveys: Results from two population-based studies. *Research on aging*, *26*(6), 655-672.

# Perceived Stress Scale - 4 Item version

Cohen, S., Kamarck, T., Mermelstein, R. (1983). A global measure of perceived stress. *Journal of Health and Social Behavior*, 24, 385-396.

# **Brief Resilience Scale (BRS)**

Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008). The brief resilience scale: assessing the ability to bounce back. *International journal of behavioral medicine*, *15*(3), 194-200.

# **Big Five Inventory-10 (BFI-10)**

Rammstedt, B., & John, O. P. (2007). Measuring personality in one minute or less: A 10-item short version of the Big Five Inventory in English and German. *Journal of research in Personality*, *41*(1), 203-212.

# **Childhood Trauma Questionnaire**

Bernstein, D. P., Stein, J. A., Newcomb, M. D., Walker, E., Pogge, D., Ahluvalia, T., ... & Zule, W. (2003). Development and validation of a brief screening version of the Childhood Trauma Questionnaire. *Child abuse & neglect*, *27*(2), 169-190.

	N° of items (+optional filter items)	Baseline	Follow-up 1	Follow-up 2	Follow-up 3	Follow-up 4	Annual Follow-up
Inclusion / Exclusion Criteria	2	2 min	-	-	-	-	2 min
Coronavirus Status	1 (+2)	<1 min	<1 min	<1 min	<1 min	<1 min	<1 min
Epidemiological factors	4 (+ 4)	2 min	2 min <sup>2</sup>	2 min <sup>2</sup>	2 min <sup>2</sup>	2 min <sup>2</sup>	2 min
Demographics	11 (+6)	1 min	-	-	-	-	1 min
Education / Professional background	3 (+4)	2 min	<1 min <sup>1</sup>	<1 min <sup>1</sup>	<1 min <sup>1</sup>	<1 min <sup>1</sup>	2 min
Home and Social Contact / SES	6 (+4)	2 min	1 min <sup>1</sup>	1 min <sup>1</sup>	1 min <sup>1</sup>	1 min <sup>1</sup>	2 min
Major life events	12	-	-	-	-	3 min	-
Comorbidities	31	3 min	-	<1 min <sup>1</sup>	<1 min <sup>1</sup>	<1 min <sup>1</sup>	3 min
Current Medication	1 (+ number medication)	1 min	-	-	-	-	1 min
Respiratory Symptoms onset	1 (+1)	<1 min	<1 min	<1 min	<1 min	<1 min	<1 min
Signs and Symptoms during the last 14 days	24 (+3)	2 min	2 min	2 min	2 min	2 min	2 min
SUB-TOTAL MINIMAL DATA SET	96 (+24)	16 min	6 min	6 min	6 min	9 min	16 min
Environmental conditions at home	10	1 min <sup>3</sup>	<1 min <sup>3</sup>				
Behavioral analysis during COVID-19 Pandemic / Compliance	11 (+3)	3 min	2 min <sup>2</sup>				
CES-D (Depression)	20	10 min	10 min	10 min	10 min	10 min	10 min
GAD-7 (Anxiety)	7	1 min	1 min	1 min	1 min	1 min	1 min
UCLA short version (Loneliness)	3	<1 min	<1 min	<1 min	<1 min	<1 min	<1 min
PSS/4 (Perceived Stress Scale)	4	<1 min	<1 min	<1 min	<1 min	<1 min	<1 min
BRS (Resilience)	6	1 min	-	-	-	-	1 min
BFI-10 (Personality)	10	1 min	-	-	-	-	1 min
Childhood Trauma Questionnaire	28	-	-	-	-	3 min	-
SUB-TOTAL EXTENDED PART	99 (+3)	18 min	14 min	14 min	14 min	17 min	14 min
TOTAL	195 (+27)	34 min	20 min	20 min	20 min	26 min	32 min

 $x^{\scriptscriptstyle 2}$  : The items marked with an  $^{\scriptscriptstyle 2} need$  to be asked only at Baseline

x<sup>3</sup>: This questionnaire needs to be asked only once (only at the moment when positive diagnosis for participant and/or for one of the household member)